Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Trulieve Cannabis Corp C.TRUL

Alternate Symbol(s):  TCNNF | C.TRUL.NT.U

Healthcare
Trulieve Cannabis Corp. is a vertically integrated cannabis company. The Company has established cannabis operations in three hubs: Southeast, Northeast, and Southwest. Its three regional hubs are anchored by market positions in cornerstone states of Florida, Pennsylvania, and Arizona. The Company operates in regulated markets that require knowledge in cultivation, manufacturing, and retail... see more

CSE:TRUL - Post Discussion

Trulieve Cannabis Corp > Trulieve Minor Cannabinoids 2022
View:
Post by Bullknit101 on Dec 30, 2021 5:01pm

Trulieve Minor Cannabinoids 2022

If you skip to minute 5:30, you'll note that Trulieve will be exploiting the market for minor cannabinoids in 2022. InMed Pharma, Willow Biosciences and Amyris might benefit. https://finance.yahoo.com/video/cannabis-fundamental-state-story-stay-152229163.html
Comment by Bullknit101 on Jan 05, 2022 9:13am
InMed will be supplying rare cannibinoids making it a good entry point (just sayin') quote: " We look forward to launching several new non-intoxicating rare cannabinoids in early 2022, including CBDV and THCV, two high demand products in the consumer health and wellness sector, and envisage significant revenue growth over the coming quarters. Our unparalleled capabilities and expertise in ...more  
Trulieve Cannabis Corp
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities